115 224

Cited 37 times in

Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma

 Kyong Joo Lee  ;  Seung Woo Yi  ;  Moon Jae Chung  ;  Seung Woo Park  ;  Si Young Song  ;  Jae Bock Chung  ;  Jeong Youp Park 
 YONSEI MEDICAL JOURNAL, Vol.54(3) : 643-649, 2013 
Journal Title
Issue Date
Adenocarcinoma/blood ; Adenocarcinoma/diagnosis* ; Adult ; Aged ; Aged, 80 and over ; Antigens, Tumor-Associated, Carbohydrate/blood* ; Carcinoembryonic Antigen/blood* ; Female ; Humans ; Male ; Middle Aged ; Pancreatic Neoplasms/blood ; Pancreatic Neoplasms/diagnosis* ; Prognosis ; Retrospective Studies ; Survival Analysis
CA 19-9 ; carcinoembryonic antigen ; pancreas adenocarcinoma ; prognosis
PURPOSE: To investigate the use of pretreatment carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) as prognostic factors to determine survival in pancreatic adenocarcinoma. MATERIALS AND METHODS: A retrospective review of the medical records of patients who were diagnosed with pancreatic adenocarcinoma and received surgery, chemoradiotherapy or chemotherapy was performed. Factors, including CA 19-9 and CEA, associated with the survival of pancreatic cancer patients were analyzed. RESULTS: Patients with the median age of 65 years were included (n=187). Elevated serum CA 19-9 levels and CEA levels were observed in 75.4% and 39% of patients at diagnosis, respectively. CEA was correlated with tumor stages (p=0.005), but CA 19-9 was not. CA 19-9 and CEA were elevated in 69.0% and 33.3% of patients with resectable pancreatic cancer, and elevated in 72.9% and 47.2% of patients with advanced pancreatic cancer, respectively. The median overall survival of the normal serum CEA group was longer than that of the elevated serum CEA group (16.3 months vs. 10.2 months, p=0.004). However, the median overall survival of the normal serum CA 19-9 group was not different from that of the elevated serum CA 19-9 group (12.4 months vs. 13.5 months, p=0.969). The independent factors associated with overall survival were advanced pancreatic cancer [harzard ratio (HR) 4.33, p=0.001] and elevated serum CEA level (HR 1.52, p=0.032). CONCLUSION: Patients with elevated serum CEA level at diagnosis demonstrated poor overall survival. Pretreatment CEA level may predict the prognosis of patients with pancreatic adenocarcinoma.
Files in This Item:
T201301016.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Seung Woo(박승우) ORCID logo https://orcid.org/0000-0001-8230-964X
Park, Jeong Youp(박정엽) ORCID logo https://orcid.org/0000-0003-0110-8606
Song, Si Young(송시영) ORCID logo https://orcid.org/0000-0002-1417-4314
Yi, Seung Woo(이승우) ORCID logo https://orcid.org/0000-0002-5929-9444
Chung, Moon Jae(정문재) ORCID logo https://orcid.org/0000-0002-5920-8549
Chung, Jae Bock(정재복)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.